Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatocellular carcinoma associated transcript 5 (HCCAT5)
- Target
- HCCAT5
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA
01
Overview
Hepatocellular carcinoma associated transcript 5 (HCCAT5) is a long non-coding RNA (lncRNA) that is selectively overexpressed in certain cancers, including hepatocellular carcinoma and gastric cancer. It is classified as an antisense lncRNA and is located on chromosome 16. HCCAT5 is not expressed in normal tissues, with specific upregulation in tumors, suggesting a role in cancer cell proliferation and survival. Knockdown studies in liver cancer cell lines indicate that reducing HCCAT5 expression impairs growth and induces apoptosis, underlining its potential as a cancer biomarker and as a novel molecular target for cancer diagnostics and therapy. No current drugs are known to target HCCAT5 directly, but its tumor-specific expression profile marks it as a compelling candidate for further research in oncology.
- Other names
- HTAFJ222407hepatoma associated genehepatoma associated proteinhepatocellular carcinoma associated transcript 5 (non-protein coding)
02
Mechanism of action
Not directly characterized, but knockdown experiments suggest that downregulation of HCCAT5: - Reduces cancer cell proliferation - May affect apoptosis pathways
03
Biological functions
Regulation of cell proliferationModulation of apoptosisPotential involvement in tumor cell viability
04
Disease associations
Cancer (notably hepatocellular carcinoma and gastric cancer)Reported low expression in normal tissues, suggesting specificity for malignant contexts
05
Safety considerations
As an RNA target, safety would depend on the delivery and specificity of therapeutic interventionNo specific clinical safety data reported; potential for off-target effects is theoretical
06
Biomarkers
Potential prognostic/diagnostic biomarker for gastric cancerPotential marker for hepatocellular carcinoma and other tumors where it is overexpressed
Beyond the preview
Go deeper on Hepatocellular carcinoma associated transcript 5 (HCCAT5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hepatocellular carcinoma associated transcript 5 (HCCAT5).